Cerebrospinal fluid (CSF) and/or plasma biomarkers, in combination with brain MRI, amyloid positron emission tomography (PET), and Apolipoprotein E (APOE) genotyping may assist in the earlier recognition of the disease and the detailed workup of patients with cognitive impairment (Figure 1) [12,13,14]. The gene discussed is APOE; the disease is Cognitive impairment.